MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met

OBJECTIVE: Lenvatinib is a first-line multikinase inhibitor for advanced hepatocellular carcinoma (HCC), but resistance to the drug remains a major hurdle for its long-term anti-cancer activity. This resistance is thought to be due to overexpression of c-Met. This study aims to identify potential up...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xin, Jiang, Wenjing, Han, Peng, Zhang, Jingyan, Tong, Liquan, Sun, Xueying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894104/
https://www.ncbi.nlm.nih.gov/pubmed/35252056
http://dx.doi.org/10.2147/JHC.S349369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894104/
https://www.ncbi.nlm.nih.gov/pubmed/35252056
http://dx.doi.org/10.2147/JHC.S349369

Ejemplares similares